Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells

Gynecologic Oncology

Volumn 104, Issue 2, 2007, Pages 443-450

  Barnes, Amber P ^a   Miller, Brigitte E ^a   Kucera, Gregory L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; Cyclooxygenase; Docetaxel; Hyperthermia; NSAID; Ovarian cancer; Paclitaxel

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; DOCETAXEL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SULINDAC SULFIDE; TAXANE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL KILLING; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; LIQUID CHROMATOGRAPHY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; TEMPERATURE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DRUG SYNERGISM; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; NITROBENZENES; OVARIAN NEOPLASMS; SULFONAMIDES; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 33846398570     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.08.008     Document Type: Article

References (41)

1. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
2. Muggia F. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Semin. Oncol. 31 Suppl. 14 (2004) 17-24
3. Hinz B., and Brune K. Cyclooxygenase-2-10 years later. J. Pharmacol. Exp. Ther. 300 2 (2002) 367-375
4. Gupta R.A., Tejada L.V., Tong B.J., Das S.K., Morrow J.D., Dey S.K., et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 63 5 (2003) 906-911
5. Munkarah A., and Ali-Fehmi R. COX-2: a protein with an active role in gynecological cancers. Curr. Opin. Obstet. Gynecol. 17 (2005) 49-53
6. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., and Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59 1 (1999) 198-204
7. Kulkarni S., Rader J., Zhang F., Liapis H., Koki A., Masferrer J., et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7 2 (2001) 429-434
8. Moos P.J., Muskardin D.T., and Fitzpatrick F.A. Effect of taxol and taxotere on gene expression in macrophages: induction of the prostaglandin H synthase-2 isoenzyme. J. Immunol. 162 1 (1999) 467-473
9. Knapp D.W., Glickman N.W., Widmer W.R., DeNicola D.B., Adams L.G., Kuczek T., et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother. Pharmacol. 46 3 (2000) 221-226
10. Hattori K., Matsushita R., Kimura K., and Nakashima E. Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth. Biol. Pharm. Bull. 24 10 (2001) 1214-1217
11. Smith W., DeWitt D., and Garavito R. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000) 145-182
12. Hildebrandt B., Wust P., Ahlers O., Dieing A., Sreenivasa G., Kerner T., et al. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol. 43 1 (2002) 33-56
13. Raaphorst G.P., Maio J., Ng C.E., and Stewart D.J. Concomitant treatment with mild hyperthermia, cisplatin and low dose-rate irradiation in human ovarian cancer cells sensitive and resistant to cisplatin. Oncol. Rep. 5 4 (1998) 971-977
14. Nakao K., Otsuki Y., Akao Y., Ito Y., Marukawa O., Tachibana S., et al. The synergistic effects of hyperthermia and anticancer drugs on induction of apoptosis. Med. Electron. Microsc. 33 1 (2000) 44-50
15. Ohno S., Siddik Z.H., Kido Y., Zwelling L.A., and Bull J.M. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chemother. Pharmacol. 34 4 (1994) 302-306
16. Hettinga J.V., Lemstra W., Meijer C., Dam W.A., Uges D.R., Konings A.W., et al. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells. Br. J. Cancer 75 12 (1997) 1735-1743
17. Meyn R.E., Corry P.M., Fletcher S.E., and Demetriades M. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res. 40 4 (1980) 1136-1139
18. Haveman J., Bergs J.W., Franken N.A., van Bree C., and Stalpers L.J. Effect of hyperthermia on uptake and cytotoxicity of cisplatin in cultured murine mammary carcinoma cells. Oncol. Rep. 14 2 (2005) 561-567
19. Greene A.K., Alwayn I.P., Nose V., Flynn E., Sampson D., Zurakowski D., et al. Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib. Ann. Surg. 242 1 (2005) 140-146
20. Yang P., Felix E., Madden T., Fischer S.M., and Newman R.A. Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins cultured tumor cells. Anal. Biochem. 308 1 (2002) 168-177
21. Gligorov J., and Lotz J.P. Preclinical pharmacology of the Taxanes: implications of the differences. Oncologist 9 Suppl. 2 (2004) 3-8
22. Klenke F., Gebhard M., Ewerbeck V., Abdollahi A., Huber P., and Sckell A. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer 6 9 (2006)
23. Ogino M., and Minoura S. Indomethacin increases the cytotoxicity of cis-platinum and 5-fluorouracil in the human uterine cervical cancer cell lines SKG-2 and HKUS by increasing the intracellular uptake of the agents. Int. J. Clin. Oncol. 6 2 (2001) 84-89
24. Altundag O., Altundag K., Morandi P., and Gunduz M. Cyclooxygenase-2 inhibitor and cisplatin combination as a radiosensitizer in the treatment of head and neck cancer patients. Ann. Oncol. 15 9 (2004) 1444-1445
25. Soriano A.F., Helfrich B., Chan D.C., Heasley L.E., Bunn Jr. P.A., and Chou T.C. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 59 24 (1999) 6178-6184
26. Shaik M.S., Chatterjee A., Jackson T., and Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int. J. Cancer 118 2 (2006) 396-404
27. Raaphorst G.P., and Yang D. The evaluation of thermal cisplatin sensitization in normal and XP human cells using mild hyperthermia at 40 and 41 degrees C. Anticancer Res. 25 4 (2005) 2649-2653
28. Debes A., Willers R., Gobel U., and Wessalowski R. Role of heat treatment in childhood cancers: distinct resistance profiles of solid tumor cell lines towards combined thermochemotherapy. Pediatr. Blood Cancer 45 5 (2006) 663-669
29. Leal B.Z., Meltz M.L., Mohan N., Kuhn J., Prihoda T.J., and Herman T.S. Interaction of hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells. Int. J. Hypertherm. 15 225 (1999) 236
30. Rietbroek R.C., Katschinski D.M., Reijers M.H., Robins H.I., Geerdink A., Tutsch K., et al. Lack of thermal enhancement for taxanes in vitro. Int. J. Hypertherm. 15 (1997) 525-533
31. Othman T., Goto S., Lee J.B., Taimura A., Matsumoto T., and Kosaka M. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology 62 (2001) 208-212
32. Schrump D.S., Zhai S., Nguyen D.M., Weiser T.S., Fisher B.A., Terrill R.E., et al. Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques. J. Thorac. Cardiovasc. Surg. 123 4 (2002) 686-694
33. Mohamed F., Marchettini P., Stuart O.A., Urano M., and Sugarbaker P.H. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann. Surg. Oncol. 10 4 (2003) 463-468
34. Gierse J.K., Hauser S.D., Creely D.P., Koboldt C., Rangwala S.H., Isakson P.C., et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biocehm. J. 305 (1995) 479-484
35. Altorki N.K., Keresztes R.S., Port J.L., Libby D.M., Korst R.J., Flieder D.B., et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J. Clin. Oncol. 21 14 (2003) 2645-2650
36. Munkarah A., Genhai Z., Morris R., Baker V.V., Deppe G., Diamond M.P., et al. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol. Oncol. 88 3 (2003) 429-433
37. Montz F.J., Monk B.J., Lacy S.M., and Fowler J.M. Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug: ability to inhibit post-radical pelvic surgery adhesions in a porcine model. Gynecol. Oncol. 48 1 (1993) 76-79
38. Lee J.H., Go A.K., Oh S.H., Lee K.E., and Yuk S.H. Tissue anti-adhesion potential of ibuprofen-loaded PLLA-PEG diblock copolymer films. Biomaterials 26 6 (2005) 671-678
39. Young L.F., Hantz H.L., and Martin K.R. Resveratrol modulates gene expression associated with apoptosis, proliferation and cell cycle in cells with mutated human c-Ha-Ras, but does not alter c-Ha-Ras mRNA or protein expression. J. Nutr. Biochem. 16 11 (2005) 663-674
40. Siwak D., Shishodia S., Aggarwal B., and Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IB kinase and nuclear factor B activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 104 4 (2005) 879-890
41. Kapitanovic S., Cacev T., Antica M., Kralj M., Cavric G., Pavelic K., et al. Effect of indomethacin on E-cadherin and (beta)-catenin expression in HT-29 colon cancer cells. Exp. Mol. Pathol. 80 1 (2006) 91-96